BioSpace News Archive

Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262 in subjects with chronic inducible urticaria.

Global eye care nonprofit, Orbis International, is kicking off a surgical training program in Zambia on board the Orbis Flying Eye Hospital - the world’s only fully accredited ophthalmic teaching hospital on board a plane.

HilleVax, Inc. today announced that it has closed its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,200,000 additional shares, at a price to the public of $12.50 per share.

Voyager Therapeutics, Inc. today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Chardan 7th Annual Genetic Medicines Conference in New York, NY, on October 2, 2023, at 5:30 p.m. ET.

Theratechnologies Inc. today announced that the Company has filed a supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin to the U.S. Food and Drug Administration (FDA) for review.

Bio-Techne Corporation (NASDAQ: TECH) today issued its 2023 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives.

Coherus BioSciences, Inc. announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the Biologics License Application supplement for UDENYCA® ONBODY™, the company’s on-body injector presentation of UDENYCA®, solely due to an ongoing review of inspection findings at a third-party filler.

HoneyNaps, the leading-edge AI-based sleep disorder diagnosis software company, has announced that its SOMNUM AI sleep disease analysis algorithm has been approved by the U.S. Food and Drug Administration (FDA).

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule.

Senores Pharmaceuticals, Inc. announced the launch of Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg, a bioequivalent and therapeutically equivalent to Cardene Capsules, 20 mg and 30 mg, of Chiesi USA , Inc. in the U.S. market.